Treatment decisions are guided by medical need rather than predefined wellness packages
PlexusDx serves non-diabetic patients pursuing weight loss through licensed 503A compounded semaglutide injections
Global, Regional, and National Burden of Diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the global burden of Disease Study 2021
Instead, they represent a distinct approach targeting craving, cue salience (what the brain pays attention to), and shared reward circuitry
Instead of rapidly escalating to higher doses, microdosing focuses on finding the minimal effective dose that provides benefits while reducing common side effects like nausea, gastrointestinal discomfort, or fatigue
Having a Letter of Medical Necessity from your healthcare provider can help prove that your weight loss treatment is part of an approved medical plan, making it more likely to qualify for health FSA or HSA use